Paradigm, BCAN Partner on Bladder Cancer Genomic Profiling | GenomeWeb

NEW YORK (GenomeWeb) – The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership aimed at improving the genomic profiling of bladder cancer. 

The partners will collaborate on a large-scale genomic study that will also include participation by medical centers. The goal is to facilitate the development of new drug treatments for bladder cancer based on a better understanding of the genomic underpinnings of the disease. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Sponsored by

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

Sponsored by

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.